TBVAC-HORIZON consortium meets for third annual progress meeting in Les Diablerets

Biofabri appoints Rolando Pajón to strengthen the late-stage development of its Tuberculosis Vaccine Candidate

Consultation meeting advances the renewed TB Vaccine Development Pathway

Les Diablerets 2026: Presentations are now available

Call for Early Career Researchers to join the CTVD meeting

Fourth call for applications to assess efficacy of Mycobacterium tuberculosis vaccine candidates

Open online consultation workshop on the renewed TB Vaccine Development Pathway – 12 February 2026

8th Global Forum for TB Vaccines to be held in April 2027 in Zaragoza, Spain

WHO launches the Global TB Report 2025

Announcement Awardees | TBVI Awards 2026

Phase 1b/2a clinical trial in adults of novel TB vaccine candidate MTBVAC shows promising results

Announcement TBVI Awards 2026

TB vaccine candidates selected for head-to-head testing

World TB Day 2025: advancing the fight against tuberculosis

Les Diablerets 2025 (presentations are now available)

TBVAC-HORIZON held its second annual progress meeting

Third call for applications to assess efficacy of Mycobacterium tuberculosis vaccine candidates

TBVI Awardees 2025

Announcement TBVI Award 2025

Mycobacterium tuberculosis vaccine candidates selected to assess efficacy in a mouse model

TBVI and EVI team up with VAC4EU

Biofabri and TBVI sign a contract with the European Health and Digital Executive Agency to accelerate the final development of the new TB vaccine MTBVAC

Vacancy at TBVI for a Management Assistant

Vacancy at TBVI for a Scientific Project Manager

7th Global Forum on TB Vaccines – Participant support

Second call for applications to assess efficacy of Mycobacterium tuberculosis vaccine candidates in a mouse model

University of Oxford (UOXF) starts aligned clinical study – first participant enrolled

7th Global Forum on TB vaccines – Call for abstracts

World Tuberculosis Day 2024 – We can End TB!

MTBVAC, the first vaccine against Tuberculosis derived from a human source, begins clinical trials in adults in India.